Acumen Pharmaceuticals (ABOS) CFO sells 6,888 shares in 10b5-1 trade

Rhea-AI Filing Summary

Acumen Pharmaceuticals CFO & Chief Business Officer Matt Zuga reported a small insider sale of company common stock. On January 8, 2026, he sold 6,888 shares at a weighted average price of $1.8166 per share, with individual trades executed between $1.72 and $1.95.

According to the disclosure, these shares were sold through an automatic “sell to cover” transaction to satisfy tax withholding obligations triggered by the vesting of restricted stock units. The transaction was made under a Rule 10b5-1 trading plan adopted on June 30, 2025. After this activity, Zuga beneficially owned 209,951 shares of Acumen Pharmaceuticals common stock.

Insider Trade Summary

Net Seller: 6,888 shares ($12,513)

Net Sell 1 txn

Insider Zuga Matt

Role CFO & Chief Business Officer

Sold 6,888 shs ($13K)

Type	Security	Shares	Price	Value
Sale	Common Stock	6,888	$1.8166	$13K

Holdings After Transaction: Common Stock — 209,951 shares (Direct)

Footnotes (1)

1. Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Form 4 Insider Transactions: What Each Field Means →

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Zuga Matt

(Last) (First) (Middle)

C/O ACUMEN PHARMACEUTICALS, INC.

1210-1220 WASHINGTON STREET, SUITE 210

(Street)

NEWTON MA 02465

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Acumen Pharmaceuticals, Inc. [ ABOS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	CFO & Chief Business Officer

3. Date of Earliest Transaction (Month/Day/Year)
01/08/2026

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	01/08/2026		S		6,888(1)	D	$1.8166(2)	209,951	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. Represents the number of shares sold by the Reporting Person through an automatic "sell to cover" transaction to satisfy tax withholding obligations in connection with the vesting of restricted stock units pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on June 30, 2025.

2. The price reported is a weighted average sales price. The shares were sold in multiple transactions at prices ranging from $1.7200 to $1.9500. Upon request, the Reporting Person will provide to the staff of the Securities and Exchange Commission, the Issuer, or any security holder of the Issuer, full information regarding the number of shares sold at each separate price within the range set forth in this footnote.

Remarks:

	/s/ Derek Meisner, Attorney-in-Fact	01/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What insider transaction did Acumen Pharmaceuticals (ABOS) report for Matt Zuga?

The filing reports that Matt Zuga, CFO & Chief Business Officer of Acumen Pharmaceuticals, sold 6,888 shares of common stock on January 8, 2026.

At what prices did Matt Zuga sell Acumen Pharmaceuticals (ABOS) shares?

The shares were sold at a weighted average price of $1.8166 per share, in multiple trades at prices ranging from $1.72 to $1.95.

Why did the Acumen Pharmaceuticals (ABOS) CFO sell 6,888 shares?

The sale represents an automatic “sell to cover” transaction to satisfy tax withholding obligations arising from the vesting of restricted stock units.

Was the Acumen Pharmaceuticals (ABOS) insider sale made under a Rule 10b5-1 plan?

Yes. The filing states the transaction was executed under a Rule 10b5-1 trading plan that Matt Zuga adopted on June 30, 2025.

How many Acumen Pharmaceuticals (ABOS) shares does Matt Zuga own after this transaction?

Following the reported sale, Matt Zuga beneficially owned 209,951 shares of Acumen Pharmaceuticals common stock.

Is Matt Zuga’s ownership in Acumen Pharmaceuticals (ABOS) direct or indirect?

The Form 4 indicates that the reported holdings and the 6,888-share sale are direct ownership positions.